Cannabinoid Receptor 1 is most recent GPCR to be targeted by RuiYi’s iCAPS platform
LA JOLLA, CA, USA and SHANGHAI, China I March 27, 2014 I RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA. RuiYi has a pipeline of innovative monoclonal antibodies to previously untargeted G protein coupled receptors (GPCRs) for important global, therapeutic needs. The financing will support the continued development of RuiYi’s lead asset, RYI-008, a novel anti-IL-6 monoclonal antibody (mAb), and the discovery and development of new therapeutic mAbs targeting GPCRs, including a first-in-class mAb to cannabinoid receptor 1 (CB-1), a commercially validated but previously intractable drug target. In addition, RuiYi expanded the leadership team, appointing Erik Karrer, Ph.D. as chief scientific officer and Brian Campion, Ph.D. as vice president of business development.
“RuiYi has a powerful antibody drug discovery platform and a unique approach to exploring and selectively targeting GPCRs as important therapeutic intervention points,” said Andy Schwab, co-founder and managing partner of 5AM Ventures. “RuiYi’s strategy to develop novel therapeutics in an emerging market is a unique opportunity to address a large and underserved patient population who have not had access to biologic therapies.”
RuiYi’s iCAPS, the leading GPCR drug discovery platform, can isolate and present functional GPCRs in their correct conformation to identify selective antibody inhibitors or activators with great specificity for more effective therapeutics. RuiYi’s first drug candidate, RYI-008, a novel anti-IL-6 monoclonal antibody, has a unique pharmacologic profile with the potential to define a new paradigm in the treatment of autoimmune diseases and cancer. Last year, RuiYi announced a collaboration with Genor BioPharma to develop the antibody in China. In addition, from iCAPS, RuiYi has identified another drug candidate, RYI-018, which is highly specific and selective to CB-1, a known therapeutically relevant and commercially validated GPCR target.
“GPCRs are well-recognized to be relevant in human disease and are significant therapeutic targets, but traditional methods could not adequately explore GPCRs as drug targets, especially if the GPCR has a small extracellular domain,” said Mr. Grayson. “From RuiYi’s iCAPS platform, we have been able to generate a fully functional antagonist to CB-1, a commercially validated GPCR target that could provide important therapeutic opportunities via a monoclonal antibody approach. With this support from our investors, we will advance RYI-018 through protein engineering for IND enabling studies.”
GPCRs are a valuable class of targets for therapeutic intervention with approximately 30 percent of today’s approved drugs modulating these proteins. Many GPCRs remain underexplored as therapeutic targets because selective targeting GPCRs and their transmembrane nature have not been amenable to classical drug discovery techniques.
Mr. Grayson concluded, “With this support from our investors, we have expanded our team and will advance RYI-018 through protein engineering for IND enabling studies and move RYI-008 into clinical trials in China. To meet their medical needs, China needs more than biosimilars, they need new, innovative therapeutics. We see our drug development strategy in China as a way to take a lead in creating new innovative medicines that could help patients around the world.”
About iCAPS
RuiYi’s iCAPS platform enables the identification of biologics with therapeutic specificity across the G-Protein Coupled Receptor (GPCR) protein family. GPCRs are a valuable class of drug targets but have been largely unexplored because of difficulty isolating GPCRs in the correct conformation and functional form as well as finding drug candidates that have the necessary specificity for therapeutic intervention. RuiYi has developed a series of technologies, termed intermembranous Conformation Antigen Presenting System or iCAPS, that enable the presentation of purified, isolated, functional and conformationally correct GPCRs optimized for generation of antibodies and other biologic modulators.
About RuiYi
RuiYi is focused on the discovery and development of novel biologic therapeutics that meet medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from it internal discovery efforts utilizing a series of the Company’s technologies, including the iCAPS (intramembranous Conformation Antigen Presenting System). Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. RuiYi’s executive management team has offices in La Jolla, California, and RuiYi’s discovery efforts and research facility are located in in the Zhangjiang Hi-Tech Park in Pudong, Shanghai, China. For more, visit www.ruiyibio.com.
SOURCE: RuiYi
Post Views: 154
Cannabinoid Receptor 1 is most recent GPCR to be targeted by RuiYi’s iCAPS platform
LA JOLLA, CA, USA and SHANGHAI, China I March 27, 2014 I RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA. RuiYi has a pipeline of innovative monoclonal antibodies to previously untargeted G protein coupled receptors (GPCRs) for important global, therapeutic needs. The financing will support the continued development of RuiYi’s lead asset, RYI-008, a novel anti-IL-6 monoclonal antibody (mAb), and the discovery and development of new therapeutic mAbs targeting GPCRs, including a first-in-class mAb to cannabinoid receptor 1 (CB-1), a commercially validated but previously intractable drug target. In addition, RuiYi expanded the leadership team, appointing Erik Karrer, Ph.D. as chief scientific officer and Brian Campion, Ph.D. as vice president of business development.
“RuiYi has a powerful antibody drug discovery platform and a unique approach to exploring and selectively targeting GPCRs as important therapeutic intervention points,” said Andy Schwab, co-founder and managing partner of 5AM Ventures. “RuiYi’s strategy to develop novel therapeutics in an emerging market is a unique opportunity to address a large and underserved patient population who have not had access to biologic therapies.”
RuiYi’s iCAPS, the leading GPCR drug discovery platform, can isolate and present functional GPCRs in their correct conformation to identify selective antibody inhibitors or activators with great specificity for more effective therapeutics. RuiYi’s first drug candidate, RYI-008, a novel anti-IL-6 monoclonal antibody, has a unique pharmacologic profile with the potential to define a new paradigm in the treatment of autoimmune diseases and cancer. Last year, RuiYi announced a collaboration with Genor BioPharma to develop the antibody in China. In addition, from iCAPS, RuiYi has identified another drug candidate, RYI-018, which is highly specific and selective to CB-1, a known therapeutically relevant and commercially validated GPCR target.
“GPCRs are well-recognized to be relevant in human disease and are significant therapeutic targets, but traditional methods could not adequately explore GPCRs as drug targets, especially if the GPCR has a small extracellular domain,” said Mr. Grayson. “From RuiYi’s iCAPS platform, we have been able to generate a fully functional antagonist to CB-1, a commercially validated GPCR target that could provide important therapeutic opportunities via a monoclonal antibody approach. With this support from our investors, we will advance RYI-018 through protein engineering for IND enabling studies.”
GPCRs are a valuable class of targets for therapeutic intervention with approximately 30 percent of today’s approved drugs modulating these proteins. Many GPCRs remain underexplored as therapeutic targets because selective targeting GPCRs and their transmembrane nature have not been amenable to classical drug discovery techniques.
Mr. Grayson concluded, “With this support from our investors, we have expanded our team and will advance RYI-018 through protein engineering for IND enabling studies and move RYI-008 into clinical trials in China. To meet their medical needs, China needs more than biosimilars, they need new, innovative therapeutics. We see our drug development strategy in China as a way to take a lead in creating new innovative medicines that could help patients around the world.”
About iCAPS
RuiYi’s iCAPS platform enables the identification of biologics with therapeutic specificity across the G-Protein Coupled Receptor (GPCR) protein family. GPCRs are a valuable class of drug targets but have been largely unexplored because of difficulty isolating GPCRs in the correct conformation and functional form as well as finding drug candidates that have the necessary specificity for therapeutic intervention. RuiYi has developed a series of technologies, termed intermembranous Conformation Antigen Presenting System or iCAPS, that enable the presentation of purified, isolated, functional and conformationally correct GPCRs optimized for generation of antibodies and other biologic modulators.
About RuiYi
RuiYi is focused on the discovery and development of novel biologic therapeutics that meet medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from it internal discovery efforts utilizing a series of the Company’s technologies, including the iCAPS (intramembranous Conformation Antigen Presenting System). Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. RuiYi’s executive management team has offices in La Jolla, California, and RuiYi’s discovery efforts and research facility are located in in the Zhangjiang Hi-Tech Park in Pudong, Shanghai, China. For more, visit www.ruiyibio.com.
SOURCE: RuiYi
Post Views: 154
